GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality

Psychoneuroendocrinology

Volumn 65, Issue , 2016, Pages 54-66

  Anderberg, Rozita H ^a   Richard, Jennifer E ^a   Hansson, Caroline ^a   Nissbrandt, Hans ^a   Bergquist, Filip ^a   Skibicka, Karolina P ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Anxiety; Depression; Exendin 4; Food intake; GLP 1; Obesity

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3A RECEPTOR; SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; PEPTIDE; VENOM;

AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; BLACK-WHITE BOX TEST; CONTROLLED STUDY; DEPRESSION; DORSAL RAPHE NUCLEUS; ELEVATED PLUS MAZE TEST; EMOTIONALITY; FOOD INTAKE; FORCED SWIM TEST; HIPPOCAMPUS; NONHUMAN; OBESITY; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; TRANQUILIZING ACTIVITY; WEIGHT REDUCTION; ANIMAL; BODY WEIGHT; BRAIN; CHEMICALLY INDUCED; DRUG EFFECTS; EMOTION; FEEDING BEHAVIOR; MALE; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY; BODY WEIGHT; BRAIN; EMOTIONS; FEEDING BEHAVIOR; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; MALE; OBESITY; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; VENOMS;

EID: 84958175636     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.11.021     Document Type: Article

References (87)

1. Anacker C., Zunszain P.A., Cattaneo A., Carvalho L.A., Garabedian M.J., Thuret S., Price J., Pariante C.M. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Mol. Psychiatry 2011, 16:738-750.
2. Anderberg R.H., Anefors C., Bergquist F., Nissbrandt H., Skibicka K.P. Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior. Physiol. Behav. 2014, 136:135-144.
3. Asan E., Steinke M., Lesch K.P. Serotonergic innervation of the amygdala: targets, receptors, and implications for stress and anxiety. Histochem. Cell Biol. 2013, 139:785-813.
4. Baggio L.L., Kim J.G., Drucker D.J. Chronic exposure to GLP-IR agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes 2004, 53:S205-S214.
5. Bananej M., Karimi-Sori A., Zarrindast M.R., Ahmadi S. D1 and D2 dopaminergic systems in the rat basolateral amygdala are involved in anxiogenic-like effects induced by histamine. J. Psychopharmacol. 2012, 26:564-574.
6. Berthoud H.R. Multiple neural systems controlling food intake and body weight. Neurosci. Biobehav. Rev. 2002, 26:393-428.
7. Bhatnagar S., Sun L.M., Raber J., Maren S., Julius D., Dallman M.F. Changes in anxiety-related behaviors and hypothalamic-pituitary-adrenal activity in mice lacking the 5-HT-3A receptor. Physiol. Behav. 2004, 81:545-555.
8. Bosker F.J., Cremers T.I., Jongsma M.E., Westerink B.H., Wikstrom H.V., den Boer J.A. Acute and chronic effects of citalopram on postsynaptic 5-hydroxytryptamine(1A) receptor-mediated feedback: a microdialysis study in the amygdala. J. Neurochem. 2001, 76:1645-1653.
9. Brubaker P.L., Crivici A., Izzo N., Ehrlich P., Tsai C.H., Drucker D.J. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology 1997, 138:4837-4843.
10. Crawley J.N. Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol. Biochem. Behav. 1981, 15:695-699.
11. Davis H.R., Mullins D.E., Pines J.M., Hoos L.M., France C.F., Compton D.S., Graziano M.P., Sybertz E.F., Strader C.D., Van Heek M. Effect of chronic central administration of glucagon-like peptide-(7-36) amide on food consumption and body weight in normal and obese rats. Obes. Res. 1998, 6:147-156.
12. de la Mora M.P., Gallegos-Cari A., Arizmendi-Garcia Y., Marcellino D., Fuxe K. Role of dopamine receptor mechanisms in the amygdaloid modulation of fear and anxiety: Structural and functional analysis. Prog. Neurobiol. 2010, 90:198-216.
13. de la Mora M.P., Gallegos-Cari A., Crespo-Ramirez M., Marcellino D., Hansson A.C., Fuxe K. Distribution of dopamine D-2-like receptors in the rat amygdala and their role in the modulation of unconditioned fear and anxiety. Neuroscience 2012, 201:252-266.
14. de Morentin P.B.M., Gonzalez-Garcia I., Martins L., Lage R., Fernandez-Mallo D., Martinez-Sanchez N., Ruiz-Pino F., Liu J., Morgan D.A., Pinilla L., Gallego R., Saha A.K., Kalsbeek A., Fliers E., Bisschop P.H., Dieguez C., Nogueiras R., Rahmouni K., Tena-Sempere M., Lopez M. Estradiol regulates brown adipose tissue thermogenesis via hypothalamic AMPK. Cell Metab. 2014, 20:41-53.
15. Del-Ben C.M., Deakin J.F., McKie S., Delvai N.A., Williams S.R., Elliott R., Dolan M., Anderson I.M. The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology 2005, 30:1724-1734.
16. Dickson S.L., Shirazi R.H., Hansson C., Bergquist F., Nissbrandt H., Skibicka K.P. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. J. Neurosci. 2012, 32:4812-4820.
17. Dixit T.S., Sharma A.N., Lucot J.B., Elased K.M. Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis. Physiol. Behav. 2013, 114:38-41.
18. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 2007, 64:327-337.
19. Egecioglu E., Engel J.A., Jerlhag E. The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS One 2013, 8.
20. Ericson E., Samuelsson J., Ahlenius S. Photocell measurements of rat motor activity. A contribution to sensitivity and variation in behavioral observations. J. Pharmacol. Methods 1991, 25:111-122.
21. Erreger K., Davis A.R., Poe A.M., Greig N.H., Stanwood G.D., Galli A. Exendin-decreases amphetamine-induced locomotor activity. Physiol. Behav. 2012, 106:574-578.
22. Govindarajan A., Rao B.S., Nair D., Trinh M., Mawjee N., Tonegawa S., Chattarji S. Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Pro. Natl. Acad. Sci. U. S. A. 2006, 103:13208-13213.
23. Grant P., Lipscomb D., Quin J. Psychological and quality of life changes in patients using GLP-1 analogues. J. Diabetes Complicat. 2011, 25:244-246.
24. Grillon C., Levenson J., Pine D.S. A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study. Neuropsychopharmacology 2007, 32:225-231.
25. Guan X. The CNS glucagon-like peptide-receptor in the control of energy balance and glucose homeostasis. Am. J. Physiol. 2014, 307:R585-R596.
26. Gulec G., Isbil-Buyukcoskun N., Kahveci N. Effects of centrally-injected glucagon-like peptide-on pilocarpine-induced seizures, anxiety and locomotor and exploratory activity in rat. Neuropeptides 2010, 44:285-291.
27. Hansson C., Alvarez-Crespo M., Taube M., Skibicka K.P., Schmidt L., Karlsson-Lindahl L., Egecioglu E., Nissbrandt H., Dickson S.L. Influence of ghrelin on the central serotonergic signaling system in mice. Neuropharmacology 2014, 79:498-505.
28. Harasta A.E., Power J.M., von Jonquieres G., Karl T., Drucker D.J., Housley G.D., Schneider M., Klugmann, M Septal glucagon-like peptide 1 receptor expression determines suppression of cocaine-induced behavior. Neuropsychopharmacology 2015, 40:1969-1978.
29. Harrell A.V., Allan A.M. Improvements in hippocampal-dependent learning and decremental attention in 5-HT3 receptor overexpressing mice. Learn. Mem. 2003, 10:410-419.
30. Hein G.J., Baker C., Hsieh J., Farr S., Adeli K. GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes 2013, 62:373-381.
31. Heisler L.K., Zhou L., Bajwa P., Hsu J., Tecott L.H. Serotonin 5-HT(2C) receptors regulate anxiety-like behavior. Genes Brain Behav. 2007, 6(49):1-496.
32. Hervas I., Queiroz C.M., Adell A., Artigas F. Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat. Br. J. Pharmacol. 2000, 130:160-166.
33. Holscher C. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases. J. Endocrinol. 2014, 221:T31-T41.
34. Holst J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007, 87:1409-1439.
35. Isacson R., Nielsen E., Dannaeus K., Bertilsson G., Patrone C., Zachrisson O., Wikstrom L. The glucagon-like peptide 1 receptor agonist exendin-improves reference memory performance and decreases immobility in the forced swim test. Eur. J. Pharmacol. 2011, 650:249-255.
36. Iwai T., Hayashi Y., Narita S., Kasuya Y., Jin K., Tsugane M., Oka J.I. Antidepressant-like effects of glucagon-like peptide-in mice occur via monoamine pathways. Behav. Brain Res. 2009, 204:235-240.
37. Jahng J.W., Kim J.G., Kim H.J., Kang D.W., Lee J.H. Chronic food restriction in young rats results in depression- and anxiety-like behaviors with decreased expression of serotonin reuptake transporter. Brain Res. 2007, 1150:100-107.
38. Kappe C., Tracy L.M., Patrone C., Iverfeldt K., Sjoholm A. GLP-1 secretion by microglial cells and decreased CNS expression in obesity. J. Neuroinflamm. 2012, 9.
39. Kastin A.J., Akerstrom V. Entry of exendin-into brain is rapid but may be limited at high doses. Int. J. Obes. Relat. Metab. Disord. 2003, 27:313-318.
40. Kelley S.P., Bratt A.M., Hodge C.W. Targeted gene deletion of the 5-HT3A receptor subunit produces an anxiolytic phenotype in mice. Eur. J. Pharmacol. 2003, 461:19-25.
41. Kimura A., Stevenson P.L., Carter R.N., Maccoll G., French K.L., Simons J.P., Al-Shawi R., Kelly V., Chapman K.E., Holmes M.C. Overexpression of 5-HT2C receptors in forebrain leads to elevated anxiety and hypoactivity. Eur. J. Neurosci. 2009, 30:299-306.
42. Kinzig K.P., D'Alessio D.A., Herman J.P., Sakai R.R., Vahl T.P., Figueiredo H.F., Murphy E.K., Seeley R.J. CNS glucagon-like peptide-receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J. Neurosci. 2003, 23:6163-6170.
43. Komsuoglu Celikyurt I., Mutlu O., Ulak G., Uyar E., Bektas E., Yildiz Akar F., Erden F., Tarkun I. Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-diabetes. Med. Sci. Monit. Basic Res. 2014, 20:112-117.
44. Krass M., Runkorg K., Vasar E., Volke V. Acute administration of GLP-1 receptor agonists induces hypolocomotion but not anxiety in mice. Acta Neuropsychiatr. 2012, 24:296-300.
45. Krass M., Volke A., Runkorg K., Wegener G., Lund S., Abildgaard A., Vasar E., Volke V. GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment. Acta Neuropsychiatr. 2015, 27:25-32.
46. Li Y., Perry T., Kindy M.S., Harvey B.K., Tweedie D., Holloway H.W., Powers K., Shen H., Egan J.M., Sambamurti K., Brossi A., Lahiri D.K., Mattson M.P., Hoffer B.J., Wang Y., Greig N.H. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Pro. Natl. Acad. Sci. U. S. A. 2009, 106:1285-1290.
47. Llewellyn-Smith I.J., Gnanamanickam G.J., Reimann F., Gribble F.M., Trapp S. Preproglucagon (PPG) neurons innervate neurochemically identified autonomic neurons in the mouse brainstem. Neuroscience 2013, 229:130-143.
48. Lopez-Rubalcava C., Lucki I. Strain differences in the behavioral effects of antidepressant drugs in the rat forced swimming test. Neuropsychopharmacology 2000, 22:191-199. 10.1016/S0893-133X(99)00100-1.
49. Lovshin J.A., Huang Q., Seaberg R., Brubaker P.L., Drucker D.J. Extrahypothalamic expression of the glucagon-like peptide-receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells. Endocrinology 2004, 145:3495-3506.
50. Lutter M., Sakata I., Osborne-Lawrence S., Rovinsky S.A., Anderson J.G., Jung S., Birnbaum S., Yanagisawa M., Elmquist J.K., Nestler E.J., Zigman J.M. The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress. Nat. Neurosci. 2008, 11:752-753.
51. McKie S., Del-Ben C., Elliott R., Williams S., del Vai N., Anderson I., Deakin J.F. Neuronal effects of acute citalopram detected by pharmacoMRI. Psychopharmacology (Berl.) 2005, 180:680-686.
52. MacLusky N.J., Cook S., Scrocchi L., Shin J., Kim J., Vaccarino F., Asa S.L., Drucker D.J. Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-receptor signaling. Endocrinology 2000, 141:752-762.
53. McQuade R., Sharp T. Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis. J. Neurochem. 1997, 69:791-796.
54. Mendez-David I., Hen R., Gardier A.M., David D.J. Adult hippocampal neurogenesis: an actor in the antidepressant-like action. Ann. Pharm. Fr. 2013, 71:143-149.
55. Merchenthaler I., Lane M., Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 1999, 403:261-280.
56. Mohammadi M., Nasehi M., Zarrindast M.R. Modulation of the effects of the cannabinoid agonist, ACPA, on spatial and non-spatial novelty detection in mice by dopamine D1 receptor drugs infused into the basolateral amygdala. Behav. Brain Res. 2015, 280:36-44.
57. Moller C., Sommer W., Thorsell A., Rimondini R., Heilig M. Anxiogenic-like action of centrally administered glucagon-like peptide-in a punished drinking tes. Prog. Neuro Psychopharmacol. Biol. Psychiatry 2002, 26:119-122.
58. Moreira F.A., Grieb M., Lutz B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23:133-144.
59. Navarro M., Hernandez E., Munoz R.M., del Arco I., Villanua M.A., Carrera M.R., Rodriguez de Fonseca F. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 1997, 8:491-496.
60. Nelson D.W., Sharp J.W., Brownfield M.S., Raybould H.E., Ney D.M. Localization and activation of glucagon-like peptide-receptors on vagal afferents in the rat. Endocrinology 2007, 148:1954-1962.
61. Nutt D.J., Forshall S., Bell C., Rich A., Sandford J., Nash J., Argyropoulos S. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur. Neuropsychopharmacol. 1999, 9(Suppl. 3):S81-S86.
62. Parker H.E., Reimann F., Gribble F.M. Molecular mechanisms underlying nutrient-stimulated incretin secretion. Expert Rev. Mol. Med. 2010, 12:e1.
63. Pellow S., Chopin P., File, Briley S.E.M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985, 14:149-167.
64. Pettersson R., Naslund J., Nilsson S., Eriksson E., Hagsater S.M. Acute escitalopram but not contextual conditioning exerts a stronger anxiogenic effect in rats with high baseline anxiety in the acoustic startle paradigm. Psychopharmacology (Berl.) 2015, 232(8):1461-1469. Epub 2014 Nov 25. PMID: 25417552. 10.1007/s00213-014-3783-z.
65. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
66. Richard J.E., Anderberg R.H., Goteson A., Gribble F.M., Reimann F., Skibicka K.P. Activation of the GLP-1 receptors in the nucleus of the solitary tract reduces food reward behavior and targets the mesolimbic system. PLoS One 2015, 10:e0119034.
67. Rossetti C., Halfon O., Boutrel B. Controversies about a common etiology for eating and mood disorders. Front. Psychol. 2014, 5(1205).
68. Santarelli L., Saxe M., Gross C., Surget A., Battaglia F., Dulawa S., Weisstaub N., Lee J., Duman R., Arancio O., Belzung C., Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.
69. Seeley R.J., Blake K., Rushing P.A., Benoit S., Eng J., Woods S.C., D'Alessio D. The role of CNS glucagon-like peptide-(7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J. Neurosci. 2000, 20:1616-1621.
70. Sharma A.N., Ligade S.S., Sharma J.N., Shukla P., Elased K.M., Lucot J.B. GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats. Metab. Brain Dis. 2015, 30:519-527.
71. Sharma A.N., Pise A., Sharma J.N., Shukla P. Dipeptidyl-peptidase IV (DPP-IV) inhibitor delays tolerance to anxiolytic effect of ethanol and withdrawal-induced anxiety in rats. Metab. Brain Dis. 2015, 30:659-667.
72. Sharma A.N., Pise A., Sharma J.N., Shukla P. Glucagon-like peptide-(GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats. Metab. Brain Dis. 2015, 30:719-730.
73. Sinclair L.I., Christmas D.M., Hood S.D., Potokar J.P., Robertson A., Isaac A., Srivastava S., Nutt D.J., Davies S.J. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br. J. Psychiatry 2009, 194:483-490.
74. Slattery D.A., Cryan J.F. Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat. Protoc. 2012, 7:1009-1014.
75. Sorensen G., Reddy I.A., Weikop P., Graham D.L., Stanwood G.D., Wortwein G., Galli A., Fink-Jensen A. The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-reduces cocaine self-administration in mice. Physiol. Behav. 2015, 149:262-268.
76. Strawn J.R., D'Alessio D.A., Keck P.E., Seeley R.J. Failure of glucagon-like peptide-to induce panic attacks or anxiety in patients with panic disorder. J. Psychiatr. Res. 2008, 42:787-789.
77. Tang-Christensen M., Larsen P.J., Thulesen J., Romer J., Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat. Med. 2000, 6:802-807.
78. Thulesen J. Glucagon-like peptide 2 (GLP-2), an intestinotrophic mediator. Curr. Protein Pept. Sci. 2004, 5:51-65.
79. Trapp S., Richards J.E. The gut hormone glucagon-like peptide-produced in brain: is this physiologically relevant?. Curr. Opin. Pharmacol. 2013, 13:964-969.
80. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., Wilding J.P., Smith D.M., Ghatei M.A., Herbert J., Bloom S.R. A role for glucagon-like peptide-in the central regulation of feeding. Nature 1996, 379:69-72.
81. Tye K.M., Mirzabekov J.J., Warden M.R., Ferenczi E.A., Tsai H.C., Finkelstein J., Kim S.Y., Adhikari A., Thompson K.R., Andalman A.S., Gunaydin L.A., Witten I.B., Deisseroth K. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature 2013, 493:537-541.
82. Vertes R.P. A PHA-analysis of ascending projections of the dorsal raphe nucleus in the rat. J. Comp. Neurol. 1991, 313:643-668.
83. Vicente M.A., Zangrossi H. Serotonin-2C receptors in the basolateral nucleus of the amygdala mediate the anxiogenic effect of acute imipramine and fluoxetine administration. Int. J. Neuropsychopharmacol. 2012, 15:389-400.
84. Wise C.D., Berger B.D., Stein L. Benzodiazepines: anxiety-reducing activity by reduction of serotonin turnover in the brain. Science 1972, 177:180-183.
85. Yang Y., Moghadam A.A., Cordner Z.A., Liang N.C., Moran T.H. Long term exendin-treatment reduces food intake and body weight and alters expression of brain homeostatic and reward markers. Endocrinology 2014, 155:3473-3483.
86. Zangrossi H., Graeff F.G. Behavioral-effects of intraamygdala injections of gaba and 5-Ht acting drugs in the elevated plus-maze. Braz. J. Med. Biol. Res. 1994, 27:2453-2456.
87. Zarrindast M.R., Mahboobi S., Sadat-Shirazi M.S., Ahmadi S. Anxiolytic-like effect induced by the cannabinoid CB1 receptor agonist, arachydonilcyclopropylamide (ACPA), in the rat amygdala is mediated through the D1 and D2 dopaminergic systems. J. Psychopharmacol. 2011, 25:131-140.